The main purpose of this study is to collect more data about how well asundexian works to prevent stroke and systemic embolism and how safe it is compared to apixaban in people with atrial fibrillation and at high risk for stroke. The study treatment, asundexian, is a new type of anticoagulant currently under development to provide further treatment options. The way it works, it aims to further improve the standard of care with regard to the risk of bleeding.
Contact phoneSparrow Clinical Research Institute | 517.364.5760
Principal investigatorDr. John Ip, MD, FACC
Trial CategoryHeart & Vascular
Trial SubCategoryAtrial Fibrillation